CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on March 27. The company’s shares closed ...

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

Novo Nordisk may miss sales expectations; federal judge fines Johnson & Johnson $1.64 billion in marketing case; CureVac mRNA ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...

CureVac (CVAC) announced that the European Patent Office has confirmed the validity of the company’s European patent EP 3 708 668 B1 subject to ...

In a legal battle between BioNTech and CureVac, the European Patent Office declared a patent owned by CureVac ...

Germany-headquartered CureVac (Nasdaq: CVAC) late Thursday announced that the European Patent Office (EPO) has confirmed the ...

Shares of CureVac (NASDAQ: CVAC) climbed 11% following a favorable patent validity decision in its legal proceedings against BioNTech (NASDAQ: NASDAQ: BNTX). The ...

recognizing CureVac's pioneering mRNA innovation EP 3 708 668 B1 describes a foundational invention of CureVac, called split poly-A tail technology, which enhances medical efficacy by improving ...

March 27 (Reuters) - The European Patent Office declared a patent owned by CureVac (5CV.DE), opens new tab, valid, after a challenge from drugmaker BioNTech (22UAy.DE), opens new tab, the company ...